Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14448382 | 1.00 | ALDH1A1 (0.61) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL13863969 | 0.98 | CYP1A2 (0.57) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL10299523 | 0.93 | CYP1A2 (0.52) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Cyclohexane SCHEMBL1243556 | 0.91 | CYP1A2 (0.46) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Cyclohexane SCHEMBL4960596 | 0.91 | CYP1A2 (0.46) | ALDH1A1CYP1A2USP2LMNATSHR | |
| Cyclohexane SCHEMBL6664121 | 0.91 | CYP1A2 (0.46) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL11032622 | 0.91 | CYP1A2 (0.46) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL4570512 | 0.89 | CYP1A2 (0.45) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL98282 | 0.89 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR | |
| SCHEMBL3421776 | 0.89 | ALDH1A1 (0.74) | ALDH1A1CYP1A2USP2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-8338478-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-7985772-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7855230-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2010-12-21 | — | — | US | disclosed |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | UCB PHARMA GMBH (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| US-7384980-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2008-06-10 | — | — | US | disclosed |
| US-7230030-B2 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| EP-1656141-A1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LTD. (GB) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | disclosed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042981-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | ALDH1A1 1088/4885CYP1A2 122/4885USP2 1225/4885 |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | ALDH1A1 928/4885CYP1A2 91/4885USP2 1446/4885 |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP1, FABP4 | ALDH1A1 521/4885CYP1A2 1508/4885USP2 2332/4885 |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | ALDH1A1 928/4885CYP1A2 91/4885USP2 1446/4885 |
| US-20100256231-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | ADRB3, TNNI3, ADRB2 | ALDH1A1 1088/4885CYP1A2 122/4885USP2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.